S6K1是瘤表现出可塑性和耐治疗性的瘤中的可向的脆弱性
Saptadwipa Ganguly1, Ravshan Burikhanov2, Vitaliy M Sviripa3
1Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
一种新型药物Super-ebastine针对S6K1以克服癌症治疗抵抗力. 这一发现为治疗具有内在或获得抵抗机制的瘤提供了新的治疗漏洞.
科学领域:
- 在瘤学瘤学.
- 化学生物学 化学生物学
- 分子生物学分子生物学
背景情况:
- 瘤通常会由于癌细胞的可塑性和异质性而对治疗产生抗性.
- 识别新的治疗点对于克服治疗耐药性癌症的克隆至关重要.
研究的目的:
- 在具有多种突变和抵抗机制的癌细胞中识别必要的蛋白质标.
- 发现新的治疗策略,以克服癌症治疗耐药性.
主要方法:
- 对抗癌细胞模型的药物库的化学生物学选.
- PRISM分析了900多个癌细胞系,以确定药物标范围.
- RNA测序,分子建模和遗传验证以识别和确认RPS6KB1 (S6K1) 作为关键目标.
主要成果:
- 一种新型的埃巴斯衍生物,超级埃巴斯 (Super-EBS),在各种突变和抵抗模型中抑制了癌细胞活力.
- 超级EBS在超过95%的测试癌症细胞系中表现出广泛的敏感性,准S6K1.
- 通过Cdc42/Rac-1/p-PAK1途径通过超级EBS诱导的亡抑制S6K1酸化,S6K1淘汰在体内废除了瘤生长.
结论:
- 核糖体蛋白S6激酶B1 (S6K1) 是瘤中一个关键的治疗漏洞.
- 用超级EBS等药物向S6K1可以克服内在和获得的治疗耐药性.
- 这项研究证实S6K1是新型癌症治疗的有希望的标.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
